 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || acarbose/orlistat (EMP16) / Empros Pharma, Xenical (orlistat) / Roche, GSK
PK/PD data, Journal: A Comparative Analysis of the Pharmacodynamic and Pharmacokinetic Properties of 2 Controlled-Release Formulations Versus a Marketed Orlistat Product. (Pubmed Central) - Jan 12, 2025
This shows that the new weight loss product MR-OA retains the dietary energy loss pathway used in Conv-O. Consistent with previous studies, minimal systemic absorption of orlistat and acarbose was observed for MR-OA, confirming that no significant alteration of the original substances occurs when modifying their release.
- ||| acarbose/orlistat (EMP16) / Empros Pharma
Enrollment closed, Trial completion date: Study Exploring the Supportive Effect of Acarbose in Weight Management (clinicaltrials.gov) - Feb 19, 2024
P2, N=320, Active, not recruiting, Sponsor: Empros Pharma AB
Consistent with previous studies, minimal systemic absorption of orlistat and acarbose was observed for MR-OA, confirming that no significant alteration of the original substances occurs when modifying their release. Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Mar 2024
- || acarbose/orlistat (EMP16) / Empros Pharma
Enrollment open: A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical (clinicaltrials.gov) - Oct 4, 2023
P1, N=20, Recruiting, Sponsor: Empros Pharma AB
Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Mar 2024 Not yet recruiting --> Recruiting
- || acarbose/orlistat (EMP16) / Empros Pharma
New P1 trial: A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical (clinicaltrials.gov) - Aug 28, 2023
P1, N=20, Not yet recruiting, Sponsor: Empros Pharma AB
- ||||| acarbose/orlistat (EMP16) / Empros Pharma
New P2 trial: Study Exploring the Supportive Effect of Acarbose in Weight Management (clinicaltrials.gov) - Jul 6, 2023
P2, N=320, Recruiting, Sponsor: Empros Pharma AB
- || acarbose/orlistat (EMP16) / Empros Pharma
Clinical, Journal: Effects of a novel weight-loss combination product containing orlistat and acarbose on obesity: A randomized, placebo-controlled trial. (Pubmed Central) - Nov 4, 2022
This trial indicates that orlistat and acarbose can be successfully combined in a modified-release formulation to provide efficacious weight loss with no unexpected safety issues. EMP16 may be a promising candidate among other medications for improved weight management.
- ||| acarbose/orlistat (EMP16) / Empros Pharma
Biomarker, Trial completion: A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary) (clinicaltrials.gov) - Apr 4, 2022
P2a, N=156, Completed, Sponsor: Empros Pharma AB
EMP16 may be a promising candidate among other medications for improved weight management. Active, not recruiting --> Completed
- || acarbose/orlistat (EMP16) / Empros Pharma
Clinical, Journal: Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose. (Pubmed Central) - Feb 23, 2022
We can therefore assume that the safety profile regarding the orlistat moiety of MR-OA is comparable to the conventional orlistat and a promising approach for weight control in obese patients. Further clinical evaluation is underway.
- || acarbose/orlistat (EMP16) / Empros Pharma
Biomarker, Enrollment closed, Trial completion date, Trial primary completion date: A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary) (clinicaltrials.gov) - Aug 20, 2021
P2a, N=156, Active, not recruiting, Sponsor: Empros Pharma AB
Further clinical evaluation is underway. Recruiting --> Active, not recruiting | Trial completion date: Apr 2021 --> Aug 2021 | Trial primary completion date: Apr 2021 --> Aug 2021
- | acarbose/orlistat (EMP16) / Empros Pharma
Biomarker, New P2a trial: A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary) (clinicaltrials.gov) - Aug 20, 2020
P2a, N=156, Recruiting, Sponsor: Empros Pharma AB